# Huashen Zhiyao Technology (Beijing)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huashen-zhiyao-technology-beijing

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.helixon.com
- Total disclosed funding: $75M
- Latest round: Series A (Jun 22, 2022)
- Investors on record: 5

## About

Based in Beijing, China and founded in 2021, Huashen Zhiyao Technology (Beijing) Co., Ltd., trading name as Helixon or Earendil Labs, operates as a pharmaceutical company that focuses on providing AI solutions to protein-based therapeutics. The company's founder Dr. Jian Peng is a professor at Tsinghua University. The research team led by him has been engaged in the fields of artificial intelligence and life sciences. In March 2026, Huashen Zhiyao Technology (Beijing) raised CNY 787 million in venture funding from DIMENSION, DST Global, Sanofi Ventures, INCE Capital, Luminous Ventures, Miracle Capital, Biotech Development Fund and other investors.

The company's technology platforms can be categorized into artificial intelligence drug development and high-throughput antibody engineering experiment. The artificial intelligence drug development includes a series of algorithms and application scenarios such as protein structure prediction, protein and antibody function prediction, key region modeling of macromolecular drugs, and protein sequence design. The high-throughput antibody engineering experiment is responsible for flow cytometry analysis, antibody screening, and evaluation of antibody binding activity and neutralization activity. Its Design platform is built for protein design, antibody discovery, protein interface optimization as well as cell engineering.

The company generates from development of new drug based on artificial intelligence technology.

## Funding rounds

- Series A, Jun 22, 2022, $75M — 5Y Capital, Gaorong Ventures, Xiang He Capital, Neumann Capital Management, GL Ventures
- Angel, Oct 20, 2021 — Xiang He Capital, GL Ventures

## Investors

- Xiang He Capital (https://capitalatlas.ai/funds/xiang-he-capital) — Angel, Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel, Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- Neumann Capital Management — Series A